Clinical Trials Logo

Immune Thrombocytopenic Purpura clinical trials

View clinical trials related to Immune Thrombocytopenic Purpura.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03395210 Active, not recruiting - Clinical trials for Immune Thrombocytopenia

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Start date: March 22, 2018
Phase: Phase 2
Study type: Interventional

This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/μL on two counts no sooner than 7 days apart in the 15 days before treatment begins. The dose-finding portion of the study has been completed. Part B treatment dose is 400 mg twice daily.